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Abstract Epidermal growth factor-binding protein (EGF-BP) is 
a serine proteinase that reversibly associates with epidermal 
growth factor (EGF). We analyzed the reaction of EGF-BP with 
urokinase type plasminogen activator (u-PA), a serine proteinase 
that promotes pericellular proteolysis and cellular migration. 
EGF-BP cleaved single chain u-PA (seu-PA) between Lys lss and 
Ile ~59, converting the zymogen into enzymatically active two- 
chain u-PA (tcu-PA), as shown by SDS-PAGE, N-terminal se- 
quence analysis, and enzymatic assay. The kcat and Km of the 
activation reaction were (5.6 -+ 0.6) × 10 -2 s -~ and 2.0 + 0.3 pM, 
yielding a catalytic efficiency of 2.8 x 10 4 M - l -  s -1. EGF-BP also 
activated scu-PA bound to receptors on U937 monocytes as dem- 
onstrated by the generation of amidase activity against a tcu-PA- 
specific fluorogenic substrate. By activating scu-PA, EGF-BP 
may initiate u-PA-dependent cell surface proteolysis and there- 
fore enhance EGF activities that require cellular migration and/or 
tissue remodeling. 
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!. Introduction 
Urokinase type plasminogen activator (u-PA) is the primary 
enzyme responsible for plasminogen activation at the cell sur- 
face (reviewed in [1]). u-PA, while bound to its cellular eceptor, 
urokinase type plasminogen activator eceptor (uPAR), acti- 
vates cell-associated plasminogen, generating plasmin. Cell-as- 
sociated plasmin directly degrades glycoproteins of the ex- 
tracellular matrix and activates metalloproteinases that digest 
extracellular matrix collagen. This u-PA-dependent cell-surface 
proteinase cascade promotes cellular migration and extracellu- 
lar matrix remodeling during several biological processes in- 
cluding chemotaxis, angiogenesis, neurite outgrowth, and 
wound repair [1]. 
*Corresponding author. University of California at San Diego, 
Medical Service 111, San Diego VAMC, 3350 La Jolla Village Dr., 
San Diego, CA 92161, USA. Fax: (1) (619) 552 7452. 
Abbreviations: EGF, epidermal growth factor; EGF-BP, EGF-binding 
protein; NGF-y, nerve growth factor-y; scu-PA, single chain urokinase 
type plasminogen activator; tcu-PA, two chain urokinase type plasmin- 
ogen activator; uPAR, urokinase type plasminogen activator receptor; 
PPACK, D-phenylalanyl-L-prolyl-arginine chloromethyl ketone; S- 
2444, L-pyroglutamyl-glycyl-arginine-p-nitroanilide hydrochloride; S-
2251, H-D-valyl-L-leucyl-L-lysine dihydrochloride; PMA, phorbol 12- 
myristate 13-acetate; PNPGB, p-nitrophenyl p'-guanidinobenzoate hy- 
drochloride; EGR-AMC, glutamyl-glycyl-arginine-7-amino-4-methyl 
coumarin; S.E.M., standard error of the mean. 
Cells synthesize u-PA as an M r 55,000 single chain zymogen 
(scu-PA) that demonstrates little or no activity against chromo- 
genie substrates or plasminogen [2,3]. Plasmin is a potent scu- 
PA activator that converts the zymogen into a two-chain form 
(tcu-PA) that is highly active against chromogenic substrates 
and plasminogen [3]. Since plasmin is present in biological 
fluids as an inactive zymogen (plasminogen), a critical question 
remains regarding initiation of u-PA-dependent cell surface 
proteolysis. Several proteinases other than plasmin activate 
scu-PA, including plasma kallikrein, tumor-associated trypsin, 
cathepsin B, cathepsin L, nerve growth factor-), (NGF-7), mast 
cell tryptase, and human T cell-associated serine proteinase 
[4-10]. Although these proteinases activate scu-PA less effi- 
ciently than plasmin, they may initiate the u-PA dependent 
proteinase cascade which can then undergo self-amplification. 
Cytokines and growth factors including epidermal growth 
factor (EGF), induce u-PA synthesis [11-14]. EGF is a small 
(Mr 6,000), widely distributed mitogen for cells of epithelial 
origin [15]. Beyond its mitogenic activity, EGF accelerates 
wound healing, enhances keratinocyte growth and migration, 
and functions as a chemoattractant for certain cell types [15 
20]. In mice, EGF associates noncovalently with an Arg/Lys 
specific serine proteinase termed EGF-binding protein (EGF- 
BP) [21,22]. The multimeric omplex, high molecular weight- 
EGF (HMW-EGF), has the stoichiometry (EGF)2(EGF-BP)2 
[21,22]. The primary function of EGF-BP probably involves 
proteolytic processing of EGF precursors [23]: other functions 
of EGF-BP are less well characterized. 
In the HMW-EGF complex, EGF-BP remains inactive due 
to association of the enzyme's active site with the C-terminal 
arg residue of EGF [21,22]. Dilution and changes in pH cause 
HMW-EGF dissociation, releasing active proteinase and 
growth factor in the same micro-environment [21,22]. However, 
it is not clear whether EGF-BP and EGF activity are coordi- 
nated in any manner. In this investigation, we show that EGF- 
BP activates cu-PA both in solution and at the cell surface. We 
hypothesize that by activating scu-PA, EGF-BP may initiate 
u-PA-dependent cell surface proteolysis and therefore nhance 
EGF-dependent activities that require cellular migration and/ 
or tissue remodeling. 
2. Materials and methods 
2.1. Reagents" 
H-D-Valyl-L-leucyl-L-lysine-p-nitroanilide d hydrochloride (S-2251) 
and L-pyroglutamyl-glycyl-arginine-p-nitroanilide hydrochloride (S- 
2444) were from Kabi Vitrum (Stockholm, Sweden). D-Phenylalanyl-L- 
prolyl-L-arginine chloromethyl ketone (PPACK) was from Chemica 
Alta (Edmonton, Alberta). Glutamyl-glycyl-arginine-7-amino-4- 
methyl coumarin (EGR-AMC) was purchased from Enzyme Systems 
(Livermore, CA). Phorbol 12-myristate 13-acetate (PMA) and p-nitro- 
phenyl p'-guanidinobenzoate hydrochloride (PNPGB) were from 
0014-5793195l$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
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Sigma. Na~251 was from Amersham International. Iodo-beads were 
from Pierce (Rockford, IL). Unless otherwise stated, reactions were 
conducted in buffer A (50 mM Tris-HCl, 100 mM NaCI, pH 7.4). 
2.2. Proteins 
EGF-BP was purified from male mouse submaxillary glands (Pel 
Freeze, Rogers, AZ) according to the method of Taylor et al. [21] and 
active site titrated with PNPGB by the method of Chase and Shaw [24]. 
In the presented experiments, he indicated EGF-BP concentrations are 
those obtained by active site titration. Dr. Jack Henkin of Abbott 
Laboratories provided the recombinant human scu-PA used in these 
studies. The scu-PA contained less than 0.5% active tcu-PA as deter- 
mined by velocity of S-2444 hydrolysis, scu-PA was radiolabeled with 
Na~25I and Enzymobeads according to the manufacturer's in tructions. 
Desalting was performed on Sephadex G-25 (Pharmacia). Specific ac- 
tivities ranged from 1-3 pCi/pg. 
2.3. Inhibition of EGF-BP by PPACK 
EGF-BP (5.5-22 nM) was incubated with 1 mM S-2251 in the sample 
cuvette of a Hewlett Packard 8450A diode array spectrophotometer. 
Reactions were conducted at 37°C in buffer A. The absorbance at406 
nm was determined at2 s intervals. After 200 s, PPACK (final concen- 
tration 60 pM) was added and absorbance monitoring continued. Ab- 
sorbance measurements were transformed with the first derivative func- 
tion (dA406/dt) o yield substrate hydrolysis velocities that are directly 
proportional to the concentration f active enzyme at any given time. 
2.4. Cleavage of scu-PA by EGF-BP 
EGF-BP (22 nM-0.44 pM) was incubated with scu-PA (10.9 ,uM) in 
buffer A for 30 min at 37°C. Reactions were terminated with PPACK 
(0.4 mM final concentration) and the products subjected to SDS-PAGE 
(8% slabs) under reducing conditions as described previously [8]. 
2.5. Identification of the EGF-BP cleavage site in scu-PA 
scu-PA (10.9 ,uM) was digested with EGF-BP (0.4 pM) in buffer A 
for 30 min at 37°C. The reaction was terminated with PPACK (0.4 mM 
final concentration) and the products analyzed by SDS-PAGE under 
reducing conditions [8]. Proteins were electrotransferred to Immobilon 
P membranes and stained with Coomassie blue (0.1% w/v). Staining 
revealed two new bands (33 kDa and 22 kDa). The 33 kDa band was 
excised and subjected to N-terminal sequence analysis (5 cycles) using 
an Applied Biosystems 470A gas-phase sequencer equipped with a 
model 120A on-line analyzer. 
2.6. Amidase activities 
Hydrolysis of S-2244 (0.125-3 raM) by EGF-BP (28 nM) was moni- 
tored at 406 nm (4 s intervals) for 500 s. Reactions were conducted at 
37°C in buffer A. An extinction coefficient of 104 M ~.cm -~ was used 
to determine the concentration fp-nitroaniline g nerated from S-2444 
hydrolysis. 
2. 7. Activation of scu-PA in solution 
scu-PA activation by EGF-BP was demonstrated with a coupled 
enzyme assay that detects the generation oftcu-PA amidase activity [8]. 
Briefly, scu-PA (0.3-3 pM) and S-2444 (1 raM, in buffer A) were 
equilibrated at 37°C in the spectrophotometer sample cuvette. Reac- 
tions were initiated by the addition of 28 nM EGF-BP. Absorbance 
readings at 406 nm were taken at 4 s intervals for 20(~500 s. Absorb- 
ance measurements were transformed with the first derivative function 
(dA4oJdt) to yield S-2444 hydrolysis velocities that are directly propor- 
tional to the concentration f active tcu-PA at any given time. Rates 
of scu-PA activation were determined from the slopes in graphs of 
tcu-PA concentration against ime [8]. 
Kinetic parameters (k~.. Km) for the activation reaction were deter- 
mined from double-reciprocal plots of velocity and concentration. 
Since EGF-BP demonstrates a low level of amidase activity against 
S-2444 (see section 3), S-2444 acts as a weak competitive inhibitor of 
EGF-BP in the coupled enzyme assay described above. Therefore, we 
corrected the apparent Km value for scu-PA activation by EGF-BP with 
the following expression: 
gMapp KM- 
(1+ [I]) 
Kr) 
[I] is the concentration f S-2444. Kr = Km for the hydrolysis of S-2444 
by EGF-BP. 
2.8. Cell culture 
U937 monocyte-like c lls [25] were obtained from the American Type 
Culture Collection and cultured as described previously [8]. Cells were 
treated with 150 nM PMA for 72 h before use. This treatment caused 
greater than 90% of the cells to become adherent. PMA also increases 
the number of u-PA receptors on the surfaces of U937 cells [26]. 
2.9. Cleavage and activation of cell-associated scu-PA by EGF-BP 
Cleavage of cell associated scu-PA by EGF-BP was analyzed after 
binding [*25I]scu-PA to U937 monocytic ells [8]. Briefly, PMA-stimu- 
lated U937 cells were treated with binding buffer (Earles Balanced Salt 
Solution containing 2 mg/ml BSA and 20 mM HEPES pH 7.4) contain- 
ing 10 mM e-aminocaproic a id and 1000 units/ml aprotinin to dissoci- 
ate any endogenously bound plasmin(ogen). The cells were subse- 
quently treated with 50 mM glycine, 100 mM NaC1, pH 3.0 for 15 min 
at 22°C to remove endogenously bound scu-PA. Cells were washed 
three times with binding buffer and then equilibrated to37°C. [125I]scu- 
PA (5 nM) was incubated with the cells for 20 min at 37°C. After 
washing, cells were treated with EGF-BP (2-200 riM) for 15 min at 
37°C. Reactions were terminated with PPACK. Cells were then washed 
twice with binding buffer, lysed, and subjected to SDS-PAGE (reducing 
conditions) and autoradiography. Cleavage of scu-PA by EGF-BP was 
quantitated byslicing the gels into 3 mm sections and counting the slices 
in a gamma counter [8]. 
To detect activation of cell-associated scu-PA by EGF-BP, we used 
the fluorogenic assay described by Wolf et al. [8]. PMA-stimulated 
U937 cells were treated to remove ndogenously bound plasmin(ogen) 
and u-PA. scu-PA (5 nM) was then incubated with the cells for 20 rain 
at 37°C. After washing to remove unbound scu-PA, 25 nM EGF-BP 
was added for 15 min at 37°C. The cells were washed again and cell- 
associated active tcu-PA was detected by the rate of hydrolysis of 
EGR-AMC (0.5 mM in buffer A) using a CytoFluor Fluorescence 
Measurement System. Excitation was at 380 nm and emission was at 
kDa 
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Fig. 1. Cleavage of scu-PA by EGF-BP in solution, scu-PA (10.9 pM) 
was reacted with EGF-BP for 0.5 h at 37°C. The products were ana- 
lyzed by SDS-PAGE on 8% slabs under educing conditions. The con- 
centrations ofEGF-BP were 0 nM (lane a), 22 nM (lane b), 44 nM (lane 
c), 0.11 pM (lane d), 0.22 pM (lane e), and 0.44 pM (lane f). 
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480 nm (slit widths of 5 nm). Fluorescence was monitored at 1 min 
intervals for 12 rain at 22°C. Background fluorescence (determined in
the absence of scu-PA) was subtracted. 
3. Results and discussion 
3.1. Inhibition of EGF-BP by PPA CK 
To determine if PPACK inhibited EGF-BP, we monitored 
S-2251 hydrolysis by EGF-BP in the absence and presence of 
the inhibitor. EGF-BP (5.5-22 nM) cleaved S-2251 at 37°C 
with substrate hydrolysis rates of 166 to 467 nM" s -1. Addition 
of 60 #M PPACK completely inhibited EGF-BP amidase activ- 
ity within the time required for mixing (2-3 s) in 3 separate 
experiments. We subsequently employed PPACK to rapidly 
inhibit EGF-BP in the experiments that follow. 
3.2. Cleavage of scu-PA by EGF-BP 
EGF-BP cleaved scu-PA into a two-chain form as demon- 
strated by SDS-PAGE under reducing conditions (Fig. 1). The 
molecular masses of the two new u-PA chains were 33 kDa and 
22 kDa. 22 nM EGF-BP cleaved significant amounts of scu-PA 
within 30 minutes. Almost complete scu-PA digestion was 
achieved with 0.44 #M EGF-BR There was no evidence for 
secondary EGF-BP cleavage sites or further digestion of the 
33-and 22-kDa products, even at the higher EGF-BP concen- 
trations. Prior incubation of EGF-BP with PPACK completely 
prevented scu-PA degradation (not shown). 
3.3. Cleavage of seu-PA by EGF-BP occurs between Lys 15~ and 
l ie  159 
To identify the EGF-BP cleavage site(s), we subjected the 33 
kDa digestion product to N-terminal sequence analysis. After 
five cycles, the only N-terminal sequence obtained was lle-Ile- 
Gly-Gly-Glu. The initial yield was 21 pmol and the repetitive 
yield was 90%. No secondary cleavage sites were detected. By 
comparison with the known sequence of scu-PA [27,28], this 
new N-terminal sequence resulted from cleavage of Lys 158- 
Ile t59, which is the same peptide bond cleaved when plasmin 
activates cu-PA [2]. 
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Fig. 2. Activation of scu-PA by EGF-BP. scu-PA was activated at 37°C 
in 50 mM Tris-HC1, 100 mM NaC1, pH 7.4 containing 1mM S-2444. 
The concentration f active EGF-BP was 28 nM. Each value represents 
the avg -2_ S.E.M. (n = 6). 
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Fig. 3. Activation of receptor-bound scu-PA by EGF-BP. scu-PA was 
bound to PMA-stimulated U937 cells as described in section 2. Cells 
that were treated with 20 nM EGF-BP for 15 rain at 37°C (E3) or 
untreated cells (z~) were washed two times with binding buffer. Subse- 
quently, 0.5 mM EGR-AMC was added to each well. Fluorescence was 
monitored at 480 nm at 1 min intervals for 12 rain at 22°C. Each value 
represents he avg + S.E.M. (n = 3). 
3.4. S-2444 Hydrolysis by EGF-BP 
EGF-BP demonstrated a low level of amidase activity against 
S-2444 in control experiments. Double reciprocal plots of S- 
2444 hydrolysis velocities versus S-2444 concentration were 
linear, indicating that EGF-BP cleaved S-2444 according to 
simple Michaelis-Menten kinetics (not shown). The k~, tand K m 
for this reaction were 5.0 + 0.1 s-' and 0.84 + 0.08 mM, respec- 
tively, yielding a catalytic efficiency (kcatlKm) of 5.8x 103 
M -~ "s-L tcu-PA hydrolyzes S-2444 with a catalytic efficien- 
cy over 150-fold greater than with EGF-BP under identical 
conditions [8]. We accounted for the low level of EGF-BP 
activity against S-2444 in the activation studies discussed 
below. 
3.5. Activation of scu-PA by EGF-BP 
Cleavage of scu-PA by EGF-BP resulted in u-PA activation 
as demonstrated by the generation of amidase activity. The 
linear Lineweaver-Burke plot shown in Fig. 2 indicates that 
EGF-BP activates cu-PA according to simple Michaelis-Men- 
ten kinetics in the substrate concentration range studied. The 
kca t and Km for the activation reaction were (5.6 + 0.6) x 10 -2 
s H and 2.0 + 0.3/,tM, yielding a catalytic efficiency (kcatlKm) of 
2.8x 104 M- I ' s  -j (Table 1). Table 1 also shows the kinetic 
parameters for the activation of scu-PA by NGF-y  and plasmin 
under identical conditions [8]. Plasmin activated scu-PA with 
a catalytic efficiency 20-fold greater than that demonstrated 
Table 1 
Kinetic parameters (avg + S.E.M., n = 6) for the activation of scu-PA 
by EGF-BP, NGF-y, and plasmin" 
Proteinase K m (tiM) kca t (S - l )  kc,tlK m 
(M -1 '  S I 
EGF-BP 2.0 + 0.3 (5.6 + 0.6) x 10-" 2.8 x 104 
NGF-y b 2.3+0.4 (4.1+0.6) x10 2 1.3x104 
Plasmin b 4.6 + 1.4 2.6 _+ 0.8 6.2 x 105 
Substrate cleavage was at 37°C in 50 mM Tris-HC1, 100 mM NaC1, 
pH 7.4 in the presence of 1 mM S-2444. 
bThese values are taken from [8]. 
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Table 2 
Cleavage of cell-associated scu-PA by EGF-BP (avg + S.E.M., n = 3)" 
EGF-BP 
2.0nM 20nM 200nM 
% scu-PA cleaved 2.6 + 0.1 6.5 + 0.9 16.7 + 0.5 
a [125i]scu_PA was bound to PMA-stimulated U937 cells. The cells were 
then washed and treated with the indicated concentrations of EGF-BP 
for 15 min at 37°C. Reactions were terminated with PPACK. Cells were 
washed again and then lysed with sample buffer. Cleavage of scu-PA 
was assessed by SDS-PAGE and autoradiography. The % scu-PA was 
determined by slicing the gels and counting the sections in a gamma 
counter. 
with EGF-BP. Therefore, EGF-BP is probably not a significant 
scu-PA activator once substantial levels of plasmin are gener- 
ated. By contrast, EGF-BP demonstrated a 2-fold greater cata- 
lytic efficiency than the related proteinase NGF-7 (Table 1) and 
over a 10-fold greater catalytic efficiency than mast cell tryptase 
(2.4x 103 M- l .s  -1, [9]). Comparison of EGF-BP with other 
scu-PA activating enzymes uch as plasma kallikrein, tumor- 
associated trypsin, and cathepsins B and L, is difficult since 
formal kinetic parameters (kc,t, K~) have not been determined 
for these enzymes [4-7]. Since all these proteinases activate 
scu-PA less efficiently than plasmin, they most likely function 
in the initiation of the u-PA-dependent cascade and not in the 
amplification phase. 
3.6. Cleavage and activation of cell-associated scu-PA by EGF- 
BP 
Since activation of receptor-bound scu-PA is essential for 
pericellular proteolysis, we examined the possibility that EGF- 
BP might also activate cell-associated scu-PA. EGF-BP cleaved 
cell-associated scu-PA, generating products that were identical 
to those formed when the scu-PA was free in solution. The 
extent of scu-PA cleavage was EGF-BP concentration-depend- 
ent (Table 2). We obtained similar results with undifferentiated 
U937 cells in suspension (not shown). 
EGF-BP activated cell-associated scu-PA as shown by the 
generation of amidase activity against the tcu-PA specific 
fluorogenic substrate EGR-AMC (Fig. 3). After incubation 
with EGF-BP, significant substrate hydrolysis was observed 
within 5 min at 22°C. In the absence of EGF-BP, u-PA activity 
was equal to background levels. Treatment of EGF-BP with 
PPACK prevented scu-PA activation at the cell surface (not 
shown). These data show that EGF-BP activates cu-PA both 
in solution and at the cell surface. Besides EGF-BP, only plas- 
min, cathepsin B, and NGF-  7 are known to activate cell-asso- 
ciated scu-PA [2,6,8]. 
Growth factors, proteinases, and proteinase inhibitors act in 
a concerted fashion to mediate the extensive cellular prolifera- 
tion, cellular migration, and tissue remodeling necessary for 
wound healing. EGF plays a pivotal role in this process by 
promoting keratinocyte proliferation, migration, and u-PA 
synthesis [14,18,19]. Keratinocyte uPAR selectively localizes 
the increased levels of u-PA secreted uring wound healing to 
the leading edge of migrating keratinocytes [29 33]. We hy- 
pothesize that by activating keratinocyte scu-PA, EGF-BP may 
initiate u-PA-dependent cell surface proteolysis and thus poten- 
tiate EGF activity during wound healing by promoting cellular 
migration and tissue remodeling. 
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